Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
Parameters | No. | Mean ± SEM | Median | p | |
Agea | |||||
≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
> 54 | 49 | 163.83 ± 8.86 | 165 | ||
Gendera | |||||
Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
Female | 15 | 164.33 ± 13.21 | 160 | ||
Tumor siteb | |||||
Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
Tongue | 7 | 170.36 ± 25.33 | 170 | ||
Others | 14 | 165.36 ± 19.25 | 171 | ||
Histological gradeb | |||||
Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
Moderate | 71 | 156.13 ± 8.35 | 160 | ||
Poor | 6 | 167.08 ± 30.81 | 183 | ||
Stagea | |||||
I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
III–IV | 56 | 178.13 ± 8.34 | 184 | ||
Tumor statusa | |||||
T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
Nodal metastasisa | |||||
Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
Present | 31 | 179.52 ± 12.64 | 180 | ||
Distant metastasisa | |||||
Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03